The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to breast cancer risk management recommendations by gene as follows: NBN – high-risk breast screening was removed as there is insufficient evidence to support high cancer risks BARD1 – added consideration for high-risk breast screening starting at age 40 …
Refine Your Search
Posts associated with "BARD1"
Permanent link to this article: https://inheritedcancer.net/post91020/
ICARE Social Media Post May 2020
Platinum Based Chemotherapy for Metastatic Pancreatic Cancer
ICARE Social Media Post May 2020
Platinum Based Chemotherapy for Metastatic Pancreatic Cancer
A recent study found that patients with metastatic pancreatic cancer who had mutations in the DNA repair genes (either inherited or just in the tumor) had better clinical outcomes after platinum-based chemotherapy compared to patients without these mutations. Check out the link to full article: https://clincancerres.aacrjournals.org/content/early/2020/05/20/1078-0432.CCR-20-0418
Permanent link to this article: https://inheritedcancer.net/post52920/
ICARE Newsletter Summer 2018
Updates to NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines
ICARE Newsletter Summer 2018
Updates to NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines
(Version 1.2019, posted July 11, 2018) Regardless of family history, some individuals with a hereditary breast- and ovarian-related cancer may benefit from genetic testing to determine eligibility for targeted treatment The multi-gene testing section table was updated with: A potential association of ATM with ovarian cancer risk Potential increased risk of BARD1 with breast cancer …
Tags: ATM, BARD1, Breast Cancer, BRIP1, Guideline/Policy Updates, Ovarian Cancer
Permanent link to this article: https://inheritedcancer.net/1nls2018/
ICARE Newsletter Summer 2017
Breast and Ovarian Cancer Associations for Genes Tested Through Multi-Gene Panels
ICARE Newsletter Summer 2017
Breast and Ovarian Cancer Associations for Genes Tested Through Multi-Gene Panels
As testing for multiple genes at the same time (“multi-gene panel testing”) has become increasingly available with tremendous advances in genetic testing technology, it has become critical to evaluate and refine cancer associations and levels of risk for many of these genes now tested. Through a commercial laboratory database of almost 100,000 results of multi-gene …
Permanent link to this article: https://inheritedcancer.net/2nls2017/
ICARE Newsletter Summer 2015
2015 NCCN Clinical Practice Guideline Update
ICARE Newsletter Summer 2015
2015 NCCN Clinical Practice Guideline Update
Breast and Ovarian Management Based on Genetic Test Resultsa Recommend Breast MRIc (>20% lifetime risk of breast cancerd) Recommend Risk-reducing salpingo-oophorectomy Discuss Option of Risk-reducing mastectomy Intervention warranted based on gene and/or risk level ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, TP53 BRCA1, BRCA2, Lynch syndromee BRCA1, BRCA2, CDH1, PTEN, TP53 Insufficient evidence …
Tags: ATM, BARD1, BRCA1, BRCA2, Breast Cancer, BRIP1, CDH1, CHEK2, Guideline/Policy Updates, Lynch Syndrome, Ovarian Cancer, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53
Permanent link to this article: https://inheritedcancer.net/1nls2015/
Inherited Cancer Registry
1500 21st Ave. So., Suite 2810
Nashville, TN 37212
Phone: (615) 875-2444
Fax: (615) 936-3648
Email: ICARE@InheritedCancer.net
Privacy Policy